ClinicalTrials.gov, http://www.clinicaltrials.gov , NCT01242293.

No abstract

No abstract

samples available for analysis (413 GDM, 383 non-GDM), 30.7% of whom had been diagnosed with Type 2 DM or metabolic syndrome. There was no difference in FGF21 level between the GDM and non-GDM groups in any of the 3 metabolic categories (Table ). Similarly, FGF21 levels did not differ between GDM women who were treated versus those that were not treated during their pregnancy (data not shown). In the entire cohort, median FGF21 levels (pg/ml) were significantly higher in women with both Type 2 diabetes (235.8 [IQR: 155.8, 411.4]) and metabolic syndrome (202.3 [IQR: 129.0, 308.6]) compared with women with no metabolic dysfunction (140.3 [IQR: 80.1, 226.4]), p<0.001. However, current metabolic status was not modified by prior GDM history, p¼0.7. CONCLUSION: FGF21 levels were not significantly different between women with a history of prior mild GDM compared with the non-GDM women at 5-10 year follow up.